Research output per year
Research output per year
Fingerprint
Dive into the research topics where Julia Katharina Schwarze is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
-
Current "state of the art" on dendritic cell-based cancer vaccines in melanoma
Schwarze, J. K., Geeraerts, X., Tuyaerts, S. & Neyns, B., 1 Mar 2023, In: Current Opinion in Oncology. 35, 2, p. 87-93 7 p.Research output: Contribution to journal › Article › peer-review
3 Citations (Scopus) -
ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-Guided Analysis
Arrieta, V. A., Duerinck, J., Burdett, K. B., Habashy, K. J., Geens, W., Gould, A., Schwarze, J. K., Dmello, C., Kim, K-S., Saganty, R., Chen, L., Moscona, A., McCord, M., Lee-Chang, C., Horbinski, C. M., Zhang, H., Stupp, R., Neyns, B. & Sonabend, A. M., 8 Nov 2023, (E-pub ahead of print) In: Clinical Cancer Research. 32 p.Research output: Contribution to journal › Article › peer-review
-
790 Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab
Tijtgat, J., Schwarze, J. K., Vander Mijnsbrugge, A-S., Raeymaeckers, S., Van Riet, I., Geeraerts, X., Stevens, L., Tuyaerts, S. & Neyns, B., 7 Nov 2022, In: Journal for immunotherapy of cancer. 10, Suppl 2Research output: Contribution to journal › Meeting abstract (Journal)
Open Access -
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors
Awada, G., Schwarze, J. K., Tijtgat, J., Fasolino, G., Kruse, V. & Neyns, B., 1 Jun 2022, In: Melanoma Research. 32, 3, p. 183-191 9 p.Research output: Contribution to journal › Article › peer-review
6 Citations (Scopus) -
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB)
Schwarze, J. K., Geens, W., Tijtgat, J., Awada, G., Seynaeve, L., Vanbinst, A-M., Everaert, H., Michotte, A., Bruneau, M., Van Riet, I., Tuyaerts, S., Duerinck, J. & Neyns, B., 1 Jun 2022, In: Journal of Clinical Oncology. 40, 16, 2033.Research output: Contribution to journal › Meeting abstract (Journal)
Open Access
Prizes
-
Best Poster Award
Awada, Gil (Recipient), Özdemir, Ibrahim (Recipient), Schwarze, Julia Katharina (Recipient), Daeninck, Emma (Recipient), Gondry, Odrade (Recipient), Jansen, Y. (Recipient), Seremet, T. (Recipient), Keyaerts, Marleen (Recipient), Everaert, Hendrik (Recipient) & Neyns, Bart (Recipient), 15 Dec 2018
Prize: Prize (including medals and awards)
-
Oral presentation 3rd prize
Schwarze, Julia Katharina (Recipient), 7 Feb 2020
Prize: Prize (including medals and awards)
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor) & Bart Neyns (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
Prognostic value of 0-(2-[18F]-fluoroethyl)-L-tyrosine PET in patients with recurrent glioblastoma.
Wietse Geens (Speaker), Stephanie Du Four (Contributor), S VAN LAERE (Contributor), Julia Katharina Schwarze (Contributor), Gil Awada (Contributor), Michaël Bruneau (Contributor), Jens Tijtgat (Contributor), Hendrik Everaert (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
962MO A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Speaker)
17 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Presenter), Jens Tijtgat (Contributor), Gil Awada (Contributor), Louise Cras (Contributor), Inès Dufait (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor) & Bart Neyns (Contributor)
17 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference